Document is current
Any future updates will be listed below
-
Authors
Hughes, Brett G. M. https://orcid.org/0000-0002-1811-0537
Mendoza, Rene Gonzalez
Basset-Seguin, Nicole
Vornicova, Olga
Schachter, Jacob
Joshi, Abhishek
Meyer, Nicolas
Grange, Florent
Piulats, Josep M.
Bauman, Jessica R.
Chirovsky, Diana
Zhang, Pingye
Gumuscu, Burak
Swaby, Ramona F.
Grob, Jean-Jacques
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03284424 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629
https://doi.org/10.1007/s13555-021-00598-6
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
https://doi.org/10.1136/jitc-2021-002757
Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.
https://doi.org/10.1200/jco.2024.42.16_suppl.9554
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma
https://doi.org/10.1136/jitc-2024-010421
-
Funding
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
- License Information
-
More Information
Article History
Received: 30 June 2021
Accepted: 18 August 2021
First Online: 23 September 2021
